Aachen, Germany-based Grunenthal GmbH has licensed rights for AstraZeneca PLC's gout medicine Zurampic (lesinurad) in Europe and Latin America whereby Britain's second biggest drug maker will receive up to $230m in sales and other milestones over the lifetime of the contract and low double-digit royalties.
AstraZeneca PLC will initially manufacture and supply Zurampic to Grunenthal and will handle the European post-approval commitment on its behalf....





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)

